{"success":true,"data":{"pressRelease":{"id":"168933","rtpr_id":"nGNX5pqsC-20261014","ticker":"SABS","exchange":"NASDAQ","all_tickers":["SABS","SABSW"],"title":"SAB BIO to Participate in Chardan 10th Annual Healthcare Conference","author":"Globe Newswire","published_at":"2026-10-14T12:30:00.362Z","article_body":"MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:\nSABS\n(https://www.globenewswire.com/Tracker?data=yKxz0sbXeKEchIsOGMqKqJQznUnQuKSP96SZII0IsIY3-GJlGq2ToGipwGoRwspWATxfFPbe_umlYDrgW-EB215FDsZYxZPXIfXDKgxpp7ifInlTPPrPWUTjHmXK8cdB35y9DRoxYdFtd8oCsghDdCnnLqXx8JAYLc06xI8DAXz7RAHx8gcWbVEo1Ubh4yEaVfXC4pO6v-afWMoBUGTXvdNwZ2_Sm3x3ujF7mQ8f07dTcBuJIlUP2dEttS702ZL3)),\na clinical-stage biopharmaceutical company developing a fully human\nanti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other\nautoimmune diseases, today announced that members of its management team will\nparticipate in the upcoming Chardan 10th Annual Healthcare Conference:\n\nDate: October 20, 2026\nTime: 11:15 - 11:30 a.m. ET\nFormat: Fireside Chat \nPresenter: Samuel J. Reich, Chief Executive Officer\nLocation: New York, NY\nWebcast: Register here\n(https://www.globenewswire.com/Tracker?data=sokeD6PUDi7M-NeY7KGoS-ta7a9dxOKZGs7Mr4vZle8ohSArE0LMY5UmJy4jr2oQRvYuOpYSNZFOt2FTSXyKq_uFDCTMFx_ZDYNTGEZvvLbqZhh_az505aprl2Y6iVZ304vGMbrLeXOsyY5APjAvIw==)\n\nSAB BIO management will be available for one-on-one meetings during the\nconference. Interested parties should contact their conference representative\nto arrange a meeting. To access replay webcasts of investor events, please\nvisit the Investors & Media\n(https://www.globenewswire.com/Tracker?data=fj90AOzOJz1s-EcTUZISV3M-75BKFTw20IbgrPOWbNOZUiuIf-bEhUXRdFWqdb4m3SkdrL1yalYor0OwzrXGbWHIrNi_bGSCqq7UYHltneSeNKB6RmTdtIomE0gfzK0FvlrTSfFy2V714nwtK1GOrQgcjThLX7_6iicR3nyb9UToFpv0k5-I2oTV6orMWrWIYCzCHp1JkcWJ0cRKFymYb1A1wh1Csmc1-jNxxEgbxA2F7RupVjscd_iuzAEc4R-xEUVZ460pDuUKfH3XIkjWYg==) section\nof SAB BIO’s website at www.sab.bio.\n\nAbout SAB BIO\nSAB BIO is a clinical-stage biopharmaceutical company focused on developing\nmulti-specific, high-potency, human immunoglobulin G (hIgG) to treat and\nprevent immune and autoimmune disorders. Using advanced genetic engineering\nand antibody science, SAB BIO developed a proprietary technology which holds\nthe potential to generate additional novel therapeutic candidates utilizing\nthe human immune response, without the need for human donors or convalescent\nplasma. SAB BIO has optimized genetic engineering in the development of\ntranschromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug\ndevelopment production system is able to generate a diverse repertoire of\nspecifically targeted, high-potency, hIgGs that can address a wide range of\nserious unmet needs in human diseases. The Company’s lead candidate,\nSAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach\nthat aims to change the T1D treatment paradigm by delaying onset and\npotentially preventing disease progression of Stage 3 T1D patients. SAB-142 is\ncurrently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients\nin a registrational Phase 2b clinical trial called SAFEGUARD. For more\ninformation, visit www.sab.bio.\n\nCONTACTS\n\nInvestor Relations:\nChristine Ryan\nir@sab.bio\n\nMedia:\nSheila Carlson\nmedia@sab.bio\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/6d99a771-f2c9-4d05-bf57-4f6c070df032)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5pqsC-20261014","title":"SAB BIO to Participate in Chardan 10th Annual Healthcare Conference","author":"Globe Newswire","ticker":"SABS","created":"2026-10-14T12:30:00.362Z","tickers":["SABS","SABSW"],"exchange":"NASDAQ","article_body":"MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:\nSABS\n(https://www.globenewswire.com/Tracker?data=yKxz0sbXeKEchIsOGMqKqJQznUnQuKSP96SZII0IsIY3-GJlGq2ToGipwGoRwspWATxfFPbe_umlYDrgW-EB215FDsZYxZPXIfXDKgxpp7ifInlTPPrPWUTjHmXK8cdB35y9DRoxYdFtd8oCsghDdCnnLqXx8JAYLc06xI8DAXz7RAHx8gcWbVEo1Ubh4yEaVfXC4pO6v-afWMoBUGTXvdNwZ2_Sm3x3ujF7mQ8f07dTcBuJIlUP2dEttS702ZL3)),\na clinical-stage biopharmaceutical company developing a fully human\nanti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other\nautoimmune diseases, today announced that members of its management team will\nparticipate in the upcoming Chardan 10th Annual Healthcare Conference:\n\nDate: October 20, 2026\nTime: 11:15 - 11:30 a.m. ET\nFormat: Fireside Chat \nPresenter: Samuel J. Reich, Chief Executive Officer\nLocation: New York, NY\nWebcast: Register here\n(https://www.globenewswire.com/Tracker?data=sokeD6PUDi7M-NeY7KGoS-ta7a9dxOKZGs7Mr4vZle8ohSArE0LMY5UmJy4jr2oQRvYuOpYSNZFOt2FTSXyKq_uFDCTMFx_ZDYNTGEZvvLbqZhh_az505aprl2Y6iVZ304vGMbrLeXOsyY5APjAvIw==)\n\nSAB BIO management will be available for one-on-one meetings during the\nconference. Interested parties should contact their conference representative\nto arrange a meeting. To access replay webcasts of investor events, please\nvisit the Investors & Media\n(https://www.globenewswire.com/Tracker?data=fj90AOzOJz1s-EcTUZISV3M-75BKFTw20IbgrPOWbNOZUiuIf-bEhUXRdFWqdb4m3SkdrL1yalYor0OwzrXGbWHIrNi_bGSCqq7UYHltneSeNKB6RmTdtIomE0gfzK0FvlrTSfFy2V714nwtK1GOrQgcjThLX7_6iicR3nyb9UToFpv0k5-I2oTV6orMWrWIYCzCHp1JkcWJ0cRKFymYb1A1wh1Csmc1-jNxxEgbxA2F7RupVjscd_iuzAEc4R-xEUVZ460pDuUKfH3XIkjWYg==) section\nof SAB BIO’s website at www.sab.bio.\n\nAbout SAB BIO\nSAB BIO is a clinical-stage biopharmaceutical company focused on developing\nmulti-specific, high-potency, human immunoglobulin G (hIgG) to treat and\nprevent immune and autoimmune disorders. Using advanced genetic engineering\nand antibody science, SAB BIO developed a proprietary technology which holds\nthe potential to generate additional novel therapeutic candidates utilizing\nthe human immune response, without the need for human donors or convalescent\nplasma. SAB BIO has optimized genetic engineering in the development of\ntranschromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug\ndevelopment production system is able to generate a diverse repertoire of\nspecifically targeted, high-potency, hIgGs that can address a wide range of\nserious unmet needs in human diseases. The Company’s lead candidate,\nSAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach\nthat aims to change the T1D treatment paradigm by delaying onset and\npotentially preventing disease progression of Stage 3 T1D patients. SAB-142 is\ncurrently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients\nin a registrational Phase 2b clinical trial called SAFEGUARD. For more\ninformation, visit www.sab.bio.\n\nCONTACTS\n\nInvestor Relations:\nChristine Ryan\nir@sab.bio\n\nMedia:\nSheila Carlson\nmedia@sab.bio\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/6d99a771-f2c9-4d05-bf57-4f6c070df032)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T12:30:00.432846819Z","server_sent_at_ms":1791981000432},"received_at":"2026-10-14T12:30:00.525Z","source_url":null},"analysis":{"id":"157177","press_release_id":"168933","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"SAB Biotherapeutics announced that management will participate in the Chardan 10th Annual Healthcare Conference with a fireside chat on October 20, 2026, at 11:15 a.m. ET in New York.\n\nCEO Samuel J. Reich will present, and management will be available for one-on-one meetings; webcast registration and replays are available via the company's website.\n\nThe release contains no new data, but it reiterates that lead candidate SAB-142 is in a registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 autoimmune type 1 diabetes patients.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance notice — no new data; suppress or note as calendar item."},"keyFigures":{},"namedEntities":{"people":[{"name":"Samuel J. Reich","role":"Chief Executive Officer"},{"name":"Christine Ryan","role":"Investor Relations contact"},{"name":"Sheila Carlson","role":"Media contact"}],"products":["SAB-142","Tc-Bovine"],"companies":[{"name":"SAB Biotherapeutics, Inc.","ticker":"SABS","relationship":"filer"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-conference participation notice with fireside chat and one-on-one meetings; no new financial, clinical, or regulatory information disclosed."},"tickerRelevance":{"others":[],"primary":"SABS"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap-clinical-stage","eventGravity":"conference-participation-notice","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SAB Biotherapeutics announced that management will participate in the Chardan 10th Annual Healthcare Conference with a fireside chat on October 20, 2026, at 11:15 a.m. ET in New York.\n\nCEO Samuel J. Reich will present, and management will be available for one-on-one meetings; webcast registration and replays are available via the company's website.\n\nThe release contains no new data, but it reiterates that lead candidate SAB-142 is in a registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 autoimmune type 1 diabetes patients.","key_figures":{},"named_entities":{"people":[{"name":"Samuel J. Reich","role":"Chief Executive Officer"},{"name":"Christine Ryan","role":"Investor Relations contact"},{"name":"Sheila Carlson","role":"Media contact"}],"products":["SAB-142","Tc-Bovine"],"companies":[{"name":"SAB Biotherapeutics, Inc.","ticker":"SABS","relationship":"filer"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:30:09.553Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap-clinical-stage","eventGravity":"conference-participation-notice","issuerAuthored":true,"newInformation":false}},"durationMs":4324,"modelName":"glm-5.3-flashx"}}